Healthcare Industry News: chronic kidney disease
News Release - May 28, 2007
Sorin Group: The Board of Directors Appoints a New Executive CommitteeMILAN, Italy--(HSMN NewsFeed)--Today, the Board of Directors of Sorin S.pA. (MIL:SRN) met and approved the following decisions:
- Professor Umberto Rosa was confirmed as Chairman and was given all executive powers for ordinary course of business
- Luca Di Giacomo was named Vice-Chairman with the role of coordinating the activities of the Chairman and the various committees in the Group to define the business strategies going forward
- An executive committee was established headed by the Chairman and composed of the following Members of the Board: Paolo Braghieri, Luca Di Giacomo, Ettore Lonati and Claudio Zulli; they will offer advice to the Chairman and the Board of Directors regarding decisions for the Group.
The Board also appointed two advisory committees: a Compensation Committee composed of Michele Cappone, Enrico Consoli and Marco Trabucchi and an Internal Audit Committee composed of Enzo Nicoli, MIchele Cappone and Andrea Mattarelli.
The Board of Directors also decided to review and propose a Stock Option plan to shareholders in the near future.
About the Sorin Group:
The Sorin Group (Bloomberg: SRN.IM; Reuters: SORN.MI), a world leader in the development of medical technologies for cardiac surgery, offers innovative therapies for cardiac rhythm dysfunctions, interventional cardiology and the treatment of chronic kidney diseases. The Sorin Group includes: Dideco, CarboMedics, Inc., COBE Cardiovascular, Inc., Stockert, Mitroflow, ELA Medical, Inc., Sorin Biomedica, Bellco and Soludia. It has more than 4,500 employees working at facilities in more than 80 countries throughout the world to serve over 5,000 public and private treatment centers. For more information, please visit: www.sorin.com
Source: Sorin Group
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.